GTS Securities LLC Has $758,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

GTS Securities LLC lowered its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 90.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,484 shares of the medical equipment provider's stock after selling 77,354 shares during the period. GTS Securities LLC's holdings in Boston Scientific were worth $758,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BSX. Colonial Trust Co SC lifted its holdings in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares during the last quarter. TFC Financial Management Inc. raised its position in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 210 shares in the last quarter. Valley National Advisers Inc. grew its holdings in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares during the last quarter. Fairway Wealth LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth about $36,000. Finally, Fourth Dimension Wealth LLC purchased a new position in Boston Scientific during the 4th quarter worth approximately $36,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 1.6%

Shares of Boston Scientific stock traded down $1.65 during trading hours on Wednesday, reaching $104.52. 6,364,220 shares of the company were exchanged, compared to its average volume of 6,404,512. The stock's fifty day moving average is $100.14 and its 200 day moving average is $97.61. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market cap of $154.63 billion, a PE ratio of 83.62, a PEG ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the firm earned $0.56 earnings per share. The business's quarterly revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This represents a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 191,155 shares of company stock worth $19,556,047. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. Evercore ISI lifted their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Finally, Robert W. Baird increased their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Twenty-three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $114.87.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.